Literature DB >> 9270568

Familial nature and continuing morbidity of the amyotrophic lateral sclerosis-parkinsonism dementia complex of Guam.

P L McGeer1, C Schwab, E G McGeer, R L Haddock, J C Steele.   

Abstract

Chamorros suffer from two neurologic syndromes known as ALS and the parkinsonism-dementia complex (PDC) of Guam. We report mortality figures for these syndromes during 1991 to 1995 and compare them with those at 5-year intervals dating back to 1951. In contrast to predictions of disease disappearance, both syndromes remain prevalent. However, age of onset and age at death have increased for both syndromes, suggesting that shifting environmental factors are causing disease postponement. We also report the clinical, familial, neuropathologic, and immunohistochemical findings on a consecutive autopsy series of Guamanian Chamorro cases. Twelve cases were diagnosed as PDC, known locally as "bodig," and three as ALS, known locally as "lytico." All but three of these fifteen patients had a pronounced family history of similar illness. Eight of twelve boding patients had siblings who were also affected with bodig; two of three lytico cases had siblings afflicted with lytico. The family histories are compatible with genetic transmission of each syndrome. The neuropathology of bodig is characterized by severe and widespread neurofibrillary tangle (NFT) development. NFTs are surrounded by reactive microglia and reactive astrocytes, and complement proteins and other molecules connected with inflammation are associated with them. Similar inflammatory responses also occur in Alzheimer's disease (AD) but have been largely attributed to the presence of senile plaques. These data indicate that tangles, as well as plaques, generate inflammatory reactions that such reactions may exacerbate the fundamental pathology in bodig as well as in AD.

Entities:  

Mesh:

Year:  1997        PMID: 9270568     DOI: 10.1212/wnl.49.2.400

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  8 in total

Review 1.  A critical review of the postulated role of the non-essential amino acid, β-N-methylamino-L-alanine, in neurodegenerative disease in humans.

Authors:  N Chernoff; D J Hill; D L Diggs; B D Faison; B M Francis; J R Lang; M M Larue; T-T Le; K A Loftin; J N Lugo; J E Schmid; W M Winnik
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2017-06-09       Impact factor: 6.393

Review 2.  Progressive supranuclear palsy: clinical features, pathophysiology and management.

Authors:  A Rajput; A H Rajput
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 3.  Frontotemporal dementia: a bridge between dementia and neuromuscular disease.

Authors:  Adeline S L Ng; Rosa Rademakers; Bruce L Miller
Journal:  Ann N Y Acad Sci       Date:  2014-12-30       Impact factor: 5.691

Review 4.  Frontotemporal Dementia.

Authors:  Nicholas T Olney; Salvatore Spina; Bruce L Miller
Journal:  Neurol Clin       Date:  2017-05       Impact factor: 3.806

5.  Predictors of breast and cervical cancer screening among Chamorro women in Southern California.

Authors:  Georgia Robins Sadler; Sheila F Lahousse; John Riley; Ben Mercado; Anne C Trinh; Lee Ann C Cruz
Journal:  J Cancer Educ       Date:  2010-03       Impact factor: 2.037

6.  Biomagnification of cyanobacterial neurotoxins and neurodegenerative disease among the Chamorro people of Guam.

Authors:  Paul Alan Cox; Sandra Anne Banack; Susan J Murch
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-11       Impact factor: 11.205

7.  A mechanism for slow release of biomagnified cyanobacterial neurotoxins and neurodegenerative disease in Guam.

Authors:  Susan J Murch; Paul Alan Cox; Sandra Anne Banack
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-04       Impact factor: 11.205

8.  Dysfunction of Protein Quality Control in Parkinsonism-Dementia Complex of Guam.

Authors:  Bert M Verheijen; Kiyomitsu Oyanagi; Fred W van Leeuwen
Journal:  Front Neurol       Date:  2018-03-20       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.